• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Reva Medical

Reva Medical cuts 44% of workforce

February 5, 2019 By Sarah Faulkner

Reva Medical updated logo

Reva Medical (ASX:RVA) said this week that it plans to cut its workforce by 44%, leaving 22 employees at the San Deigo-based company. In a statement, Reva CEO Reggie Groves cited current market conditions as the primary reason for the staffing reduction. “While we continue to see strong interest in Fantom Encore and are excited about […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

Reva brings bioresorbable scaffolds to new markets

January 9, 2019 By Sarah Faulkner

Reva Medical updated logo

Reva Medical (ASX:RVA) said this week that it inked four new distribution agreements, bringing its commercial operations to seven European countries. The San Diego, Calif.-based company said the deals serve to expand the reach of its drug-eluting bioresorbable scaffold, Fantom Encore. Reva said it landed deals with the following companies: A care a.s. in the Czech […]

Filed Under: Business/Financial News, Distribution, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

How Reggie Groves reinvented Medtronic’s atrial fibrillation biz

December 7, 2018 By Sarah Faulkner

DeviceTalks West

Reva Medical (ASX:RVA) CEO Reggie Groves got her start in the medical device industry at medtech titan Medtronic. In her upcoming keynote interview at DeviceTalks West, Groves will discuss how that experience has shaped her as a leader and an innovator. Here’s a preview: When Reggie Groves joined Medtronic (NYSE:MDT) in 2002, she didn’t know very much about […]

Filed Under: Business/Financial News, Featured, Vascular, Wall Street Beat Tagged With: DeviceTalks West, johnsonandjohnson, Medtronic, Reva Medical, St. Jude

Reva touts first implant of Fantom Encore bioresorbable scaffold in Italy

December 5, 2018 By Sarah Faulkner

Reva Medical updated logo

Reva Medical (ASX:RVA) touted this week the first implant of its newly-launched Fantom Encore bioresorbable scaffold in Italy. The company’s third-generation coronary bioresorbable scaffold features a thin strut profile and Reva’s Tyrocore polymer. “The patient I treated today was young, only 53 years old, and a perfect candidate for bioresorbable scaffolds,” Antonio Colombo of the Columbus […]

Filed Under: Drug-Device Combinations, Featured, Implants, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

Sales for Reva Medical up in Q3 following launch of bioresorbable scaffold

November 6, 2018 By Sarah Faulkner

Reva Medical

Shares in Reva Medical (ASX:RVA) rose today after the medical device maker posted its third-quarter financial results. The San Diego, Calif.-based company recorded a net loss of -$9 million on sales of $93,000 for the 3 months ended Sept. 30, for sales growth of 447% compared with the same period last year. Earnings per share were […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

Reva launches Fantom Encore bioresorbable scaffold

November 1, 2018 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) said this week that it launched its Fantom Encore bioresorbable, drug-eluting scaffold and that the first person was treated in a post-market trial of the device. The Fantom Encore product is a third-gen coronary bioresorbable scaffold featuring a thin strut profile and Reva’s Tyrocore polymer. Reva noted that the device will be made […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

Reva wins CE Mark for bioresorbable scaffold in below-the-knee PAD

July 26, 2018 By Fink Densford

Reva Medical

Reva Medical (ASX:RVA) said yesterday it won CE Mark approval in the European Union for its Motiv bioresorbable drug-eluting scaffold, now cleared for treatment of below-the-knee peripheral artery disease. The San Diego-based company’s Motiv is made from the company’s proprietary radiopaque Tyrocore polymer designed for vascular scaffolds. Reva said that over the coming months, it will […]

Filed Under: Drug-Device Combinations, Featured, Regulatory/Compliance, Stents, Vascular Tagged With: Reva Medical

Reva lands new partner in Italy for bioresorbable scaffold

July 17, 2018 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) said today that it inked a deal with Bio Vascular Group to distribute Reva’s Fantom bioresorbable scaffold in Italy. The partnership expands Reva’s commercial activities to Italy, adding to its ongoing efforts in Germany, Switzerland, Austria and Turkey. The San Diego, Calif.-based company also touted today that the first commercial implant of its […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

Reva Medical wins CE Mark for full line of Fantom Encore bioresorbable scaffolds

June 21, 2018 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) said this week that it won CE Mark clearance for its entire line of Fantom Encore bioresorbable, drug-eluting scaffolds. The new approval covers Reva’s Fantom 3.0 and 3.5 mm diameter devices, helping the company expand beyond its already-approved 2.5 mm diameter scaffold. Reva’s third-generation coronary bioresorbable scaffold features a thinner strut profile than […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Vascular, Wall Street Beat Tagged With: Reva Medical

Reva Medical’s Fantom bioresorbable scaffold succeeds in two-year trial

May 25, 2018 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) touted sustained safety and efficacy results for its Fantom bioresorbable scaffold at this year’s EuroPCR meeting. The company also revealed new information about its suite of Fantom Encore products, noting that the devices will have strut profiles of 95 microns, 105 microns and 115 microns. Reva’s Fantom II trial included 240 patients and […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Vascular, Wall Street Beat Tagged With: Reva Medical

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS